Jon also confirming they have had a number of discussions regarding licensing, takeover and that they are not going to decide until after the FDA meeting next month. (Presumably to get the best value/outcome). Also confirmed our theory that they will be prepared to fund 2 phase 3 without any capital raisings but the likelihood of a transaction occurring from then would be increased. 2 phase 3's is fantastic but there's an opportunity for much more to be occurring and for this drug to be a 10b+ sales monster.
Ann: Phase 2 trial shows significant improvements in Angelman, page-52
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$13.12 |
Change
0.265(2.06%) |
Mkt cap ! $1.635B | |||
| Open | High | Low | Value | Volume |
| $13.15 | $13.37 | $12.92 | $4.744M | 361.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 143 | $13.11 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.12 | 243 | 5 |
View Market Depth
| Last trade - 13.05pm 18/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |